Evidence map›Paper›PMID 41487431›Full record

ArticleFrontiers in neurology2025

Canadian Creutzfeldt-Jakob disease incidence remained stable during the coronavirus disease (COVID-19) pandemic.

Jessy A Slota, Dobrila Todoric, Vanessa Bergeron, Kristen Avery, Clark Phillipson, Dominic M S Kielich, Jennifer Myskiw, Lise Lamoureux, Kathy Frost, Sharon L R Simon and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jessy A SlotaMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Dobrila TodoricInfectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON, Canada.
Vanessa BergeronInfectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON, Canada.
Kristen AveryMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Clark PhillipsonMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Dominic M S KielichMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Jennifer MyskiwMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Lise LamoureuxMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Kathy FrostMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Sharon L R SimonMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Ben A Bailey-ElkinMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Stephanie A BoothMycobacteriology, Vector-Borne and Prion Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Healthcare disruptions imposed by the coronavirus disease (COVID-19) pandemic and possible biological links between SARS-CoV-2 and prion misfolding might influence the prevalence or characteristics of Creutzfeldt-Jakob Disease (CJD). This report investigates the potential impact of the COVID-19 pandemic on Canadian CJD diagnostics and surveillance from 2016-2025. Methods: Canada-wide CJD diagnostic findings from end-point quaking induced conversion (EP-QuIC) cerebrospinal fluid (CSF) assays were compared across three periods: pre- (2016-01-29 - 2020-02-28), during (2020-03-01 - 2022-09-30), and post-COVID-19 (2022-10-01 - 2025-09-29). Presented are incidence rates and distributions of biomarker abundances, case demographics, CJD molecular subtypes, and disease durations. Results: While EP-QuIC test submissions increased during the pandemic, CJD incidence was unaltered and not associated with SARS-CoV-2 incidence. Demographics, disease durations, and molecular subtypes of sporadic CJD (sCJD) were largely consistent across periods, although a higher proportion of females were tested during COVID and the prevalence of sCJD MV1 declined post-COVID. Conclusion: CJD prevalence and characteristics remained stable during COVID-19 despite increased EP-QuIC test submissions. These findings verify that CJD surveillance in Canada remained vigilant during the pandemic and highlight the value of EP-QuIC CSF testing for comprehensive CJD monitoring.

Indexed as

coronavirus diseaseCreutzfeldt-Jakob diseasediagnosticsprion diseaseSARS-CoV-2surveillance

Identifiers

PMID41487431
PMCPMC12757214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.